Immuneering Corp (IMRX)
5.17
+1.47%
Immuneering Corp (IMRX) is currently trading at $5.17. This represents a gain of 1.47% from the previous session. With a market capitalization of $0.34B, IMRX is a key component of the Health Care sector. Investors looking to trade IMRX should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Get 15 Free Stocks on Moomoo →
T&Cs Apply. Trade IMRX commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Immuneering Corp (IMRX) shows a bullish trend. Analysts are watching the 5.30 level closely.
Fundamentals
Mkt Cap0.34B
P/E Ratio0.0000
Volume460,872
60-Day Technical Chart
Advanced Charting
Need more indicators for IMRX? Use the world's #1 platform.
Open IMRX on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $5
| Metric |
IMRX +1.47% |
OPEN -3.62% |
NIO -1.79% |
SNAP +1.91% |
|---|---|---|---|---|
| Price | $5.17 | $4.97 | $5.21 | $5.06 |
| Mkt Cap | $0.34B | $4.75B | $12.74B | $8.52B |
| - | View → | View → | View → |
Latest Headlines
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX)
Yahoo Finance • Sep 30, 2025
Immuneering stock falls after reporting survival data for pancreatic cancer drug
Investing.com • Jan 7, 2026
$IMRX stock is up 22% today. Here's what we see in our data.
Quiver Quantitative • Jan 7, 2026
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer
Seeking Alpha • Jan 7, 2026
94% 6-Month Survival Rate: Immuneering's Pancreatic Cancer Drug Attracts $25M Investment at Premium
Stock Titan • Aug 21, 2025
● Gemini Agentic AI Analyst Insight for IMRX
Market Education
- What do these rich Traders do - Peek into their day Jul 15, 2023
- Finding Stocks in the Squeeze Zone: Using Finviz Jul 30, 2023
- I am a newbie Trader, how do I start trading Jul 15, 2023
External Research